Alnylam and Regeneron will work on RNAi therapies for ocular, CNS, and liver disease indications in a $1.15bn alliance. Novartis paid $310m up front for IFM Tre, which focuses on abnormal NLRP3 inflammasome activation. Biopharma financing was down in April compared with the previous month, but device funding increased.
Top Alliances In April 2019
POTENTIAL DEAL VALUE IS THE SUM OF UP-FRONT FEES PLUS PRE- AND POST-COMMERCIALIZATION MONEY.Medtrack; Strategic Transactions | Pharma Intelligence, 2019
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.
Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
